Efficacy and safety of prolonged-release OROS methylphenidate in adults with attention deficit/hyperactivity disorder: A 13-week, randomized, double-blind, placebo-controlled, fixed-dose study

References

• Adler LA, Zimmerman B, Starr HL, Silber S, Palumbo J, Orman C, et al. 2009. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. J Clin Psychopharmacol 29:239–247.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. 2000. Diagnostic and statistical manual of mental disorders. 4th edn, text revision. Washington, DC: American Psychiatric Association.
   Google Scholar
• Barkley RA, Fischer M, Smallish L, Fletcher K. 2006. Young adult outcome of hyperactive children: adaptive functioning in major life activities. J Am Acad Child Adolesc Psychiatry 45:192–202.
   PubMed Web of Science ®Google Scholar
• Baron RM, Kenny DA. 1986. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol 51:1173–1182.
   PubMed Web of Science ®Google Scholar
• Biederman J, Mick E, Faraone SV. 2000. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry 157:816–818.
   PubMed Web of Science ®Google Scholar
• Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Harpold T, et al. 2006. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 59:829–835.
   PubMed Web of Science ®Google Scholar
• Biederman J, Mick EO, Surman C, Doyle R, Hammerness P, Michel E, et al. 2007. Comparative acute efficacy and tolerability of OROS and immediate release formulations of methyl phenidate in the treatment of adults with attention-deficit/hyperactivity disorder. BMC Psychiatry 7:49.
   PubMed Web of Science ®Google Scholar
• Biederman J, Petty CR, Fried R, Kaiser R, Dolan CR, Schoenfeld S, et al. 2008. Educational and occupational underattainment in adults with attention-deficit/hyperactivity disorder: a controlled study. J Clin Psychiatry 69:1217–1222.
   PubMed Web of Science ®Google Scholar
• Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Kotarski M, et al. 2010. A randomized, 3-phase, 34-week, double-blind, long-term efficacy study of osmotic-release oral system-methylphenidate in adults with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 30:549–553.
   PubMed Web of Science ®Google Scholar
• Bouffard R, Hechtman L, Minde K, Iaboni-Kassab F. 2003. The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Can J Psychiatry 48:546–554.
   PubMed Web of Science ®Google Scholar
• Buitelaar JK, Ramos-Quiroga JA, Casas M, Kooij JJ, Niemelä A, Konofal E, et al. 2009. Safety and tolerability of flexible dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Neuropsychiatr Dis Treat 5:457–466.
   PubMed Web of Science ®Google Scholar
• Conners C, Erhardt D, Sparrow E. 1999. Conners’ Adult ADHD Rating Scales (CAARS): Technical manual. North Tonawanda, NY: Multi-Health Systems.
   Google Scholar
• De Graaf R, Kessler RC, Fayyad J, ten Have M, Alonso J, Angermeyer M, et al. 2008. The prevalence and effects of adult attention-deficit/hyperactivity disorder (ADHD) on the performance of workers: results from the WHO World Mental Health Survey Initiative. Occup Environ Med 65:835–842.
   PubMed Web of Science ®Google Scholar
• Fayyad J, De Graaf R, Kessler R, Alonso J, Angermeyer M, Demyttenaere K, et al. 2007. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry 190:402–409.
   PubMed Web of Science ®Google Scholar
• First M, Spitzer R, Gibbon M, Spitzer RL, Williams JBW, Benjamin LS. 1994. Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-P), version 2. New York: New York State Psychiatric Institute, Biometrics Research.
   Google Scholar
• Goodman DW. 2007. The consequences of attention-deficit/hyperactivity disorder in adults. J Psychiatr Pract 13:318–327.
   PubMedGoogle Scholar
• Guy W. 1976. HAMA Hamilton Anxiety Scale. In: Guy W, editor. ECDEU Assessment Manual, revised, pp. 194–198. Rockville, MD: US Department of Health and Human Services, Public Health Service – Alcohol, Drug Abuse, and Mental Health Administration.
   Google Scholar
• Hamilton M. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62.
   PubMed Web of Science ®Google Scholar
• Jain U, Hechtman L, Weiss M, Ahmed TS, Reiz JL, Donnelly GA, et al. 2007. Efficacy of a novel biphasic controlled- release methylphenidate formula in adults with attention-deficit/hyperactivity disorder: results of a double-blind, placebo- controlled crossover study. J Clin Psychiatry 68:268–277.
   PubMed Web of Science ®Google Scholar
• Kessler RC, Adler L, Ames M, Barkley RA, Birnbaum H, Greenberg P, et al. 2005. The prevalence and effects of adult attention deficit/hyperactivity disorder on work performance in a nationally representative sample of workers. J Occup Environ Med 47:565–572.
   PubMed Web of Science ®Google Scholar
• Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, et al. 2006. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 163:716–723.
   PubMed Web of Science ®Google Scholar
• Kooij JJ, Burger H, Boonstra AM, Van der Linden PD, Kalma LE, Buitelaar JK. 2004. Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder: a randomized placebo-controlled double-blind cross-over trial. Psychol Med 34:973–982.
   PubMed Web of Science ®Google Scholar
• Kooij JJ, Buitelaar JK, van den Oord EJ, Furer JW, Rijnders CA, Hodiamont PP. 2005. Internal and external validity of attention-deficit hyperactivity disorder in a population-based sample of adults. Psychol Med 35:817–827.
   PubMed Web of Science ®Google Scholar
• Landgraf JM. 2007. Monitoring quality of life in adults with ADHD: reliability and validity of a new measure. J Atten Disord 11:351–362.
   PubMedGoogle Scholar
• Mannuzza S, Klein RG, Moulton JL 3rd. 2003. Persistence of attention-deficit/hyperactivity disorder into adulthood: what have we learned from the prospective follow-up studies? J Atten Disord 7:93–100.
   PubMedGoogle Scholar
• Medori R, Ramos-Quiroga JA, Casas M, Kooij JJ, Niemelä A, Trott GE, et al. 2008. A randomized, placebo-controlled trial of 3 fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 63:981–989.
   PubMed Web of Science ®Google Scholar
• National Collaborating Centre for Mental Health 2008. Attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults. London: National Institute for Health and Clinical Excellence.
   Google Scholar
• National Institute for Mental Health (NIMH) 1985. CGI (Clinical Global Impression Scale). Psychopharmacol Bull 21:843.
   Google Scholar
• Rösler M, Fischer R, Ammer R, Ose C, Retz W. 2009. A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci 259:120–129.
   PubMed Web of Science ®Google Scholar
• Rösler M, Casas M, Konofal E, Buitelaar J. 2010. Attention deficit hyperactivity disorder in adults. World J Biol Psychiatry 11:684–698.
   PubMed Web of Science ®Google Scholar
• Secnik K, Swensen A, Lage MJ. 2005. Comorbidities and costs of adult patients diagnosed with attention-deficit hyperactivity disorder. Pharmacoeconomics 23:93–102.
   PubMed Web of Science ®Google Scholar
• Sheehan DV, Harnett-Sheehan K, Raj BA. 1996. The measurement of disability. Int Clin Psychopharmacol 11(Suppl 3):89–95.
   Google Scholar
• Spencer T, Biederman J, Wilens T, Doyle R, Surman C, Prince J. 2005. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 57:456–463.
   PubMed Web of Science ®Google Scholar
• Starr HL, Armstrong RB, Ma Y-W, Ascher S. 2010. Individualized dosing with OROS® methylphenidate to optimize treatment in adults with attention-deficit/hyperactivity disorder. Presented at the 2010 US Psychiatric & Mental Health Congress, Orlando, FL, USA.
   Google Scholar
• Tarter R, Hegedus A. 1991. The Drug Use Screening Inventory: its application in the evaluation and treatment of alcohol and drug abuse. Alcohol Health Res World 15:65–75.
   Google Scholar